Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: zandant, LilKahuna, BooDog, MXAMDUD, TheHound, Lemoncat
Search This Board: 
Last Post: 4/2/2020 11:40:21 PM - Followers: 834 - Board type: Free - Posts Today: 1

Innovation Pharmaceuticals Inc. (IPIX)

 
$$ Brilacidin - Potential Novel Coronavirus Treatment $$
 

Brilacidin shipping to U.S. Regional Biocontainment Laboratory
for Research Against Coronavirus COVID-19



http://www.nbc-2.com/story/41862764/innovation-pharmaceuticals-signs-second-mta-to-explore-brilacidin-as-coronavirus-covid-19-treatment

https://www.nbc-2.com/story/41825546/innovation-pharmaceuticals-to-ship-brilacidin-to-us-regional-biocontainment-laboratory-for-research-against-coronavirus-covid-19

https://www.otcmarkets.com/filing/html?id=13957689&guid=HGECUnyCPTlM93h

SEC Filings  https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management:  http://www.ipharminc.com/senior-management/

Scientific Advisors:  http://www.ipharminc.com/scientific-advisors/

Clinical Trials:  https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name:   https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps

 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

PIPELINE: 
CLICK TO VIEW LARGER IMAGE

 

FDA DESIGNATIONS:

 

Stages of development:

stages-v2.jpg


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Innovation Pharmaceuticals IP



Patent Filings:


EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Chart:   https://stockcharts.com/h-sc/ui?s=IPIX

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Current Report Filing (8-k) 03/06/2020 12:01:06 PM
IPIX News: Current Report Filing (8-k) 02/27/2020 12:01:14 PM
IPIX News: Current Report Filing (8-k) 02/13/2020 04:06:02 PM
IPIX News: Quarterly Report (10-q) 02/13/2020 04:02:49 PM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 12/26/2019 05:19:40 PM
PostSubject
#289459  Sticky Note IPIX Receives Data for Direct Inhibition of SARS-CoV-2, LilKahuna 04/01/20 11:33:02 AM
#284697  Sticky Note Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin TheHound 03/06/20 12:28:07 PM
#283766  Sticky Note The MERS and SARS epidemics were both coronaviruses farrell90 03/01/20 03:52:14 PM
#267390  Sticky Note The other point which makes this more significant farrell90 07/13/19 01:38:49 PM
#249866  Sticky Note BOARD WARNING: Please read - IH Admin [Shelly] 11/26/18 10:31:07 AM
#290294   JM Barry is great. I have his KarinCA 04/03/20 01:42:23 AM
#290293   Just spent the last 2 hours sending Paddleboarder 04/02/20 11:40:21 PM
#290292   Thank you Karin! This misinformation is all they Cognition 04/02/20 11:37:29 PM
#290291   This is who Anderson Cooper was quoting: CallMeCrazy 04/02/20 11:17:42 PM
#290290   Amen blubusdrvr 04/02/20 11:16:07 PM
#290289   Incorrect. Following is from the other companies KarinCA 04/02/20 11:01:02 PM
#290288   Charting T&A? Luckytouch 04/02/20 11:00:46 PM
#290285   Karin, it cracked me up, Anderson Cooper just taas 04/02/20 10:21:52 PM
#290284   Yes. I listened to the entire thing. multiples 04/02/20 10:20:26 PM
#290283   What I don't understand is with all this mightymk 04/02/20 10:13:50 PM
#290282   Recap of company trials... KarinCA 04/02/20 10:07:56 PM
#290281   Somebody have info about LW meeting today? Papaul21 04/02/20 10:02:40 PM
#290280   Another good read tonight these were smart folks livefree_ordie 04/02/20 10:00:19 PM
#290279   At the risk of being called a cynic Empiricst1 04/02/20 09:59:43 PM
#290278   Yep... that other company hasn't had a single KarinCA 04/02/20 09:53:09 PM
#290276   Ipix is a Stockholm syndrome situation for many. scottsmith 04/02/20 09:46:39 PM
#290275   Aaaaaahhhh no!!! Thanks for the entertainment! triangle and 2 04/02/20 09:40:40 PM
#290274   Forgetting that both Menon and Leo are named Unattached 04/02/20 09:35:02 PM
#290273   Yep... that company hasn't had a single clinical KarinCA 04/02/20 09:29:24 PM
#290271   Yeah next deal likely napalm em. williamssc 04/02/20 09:17:47 PM
#290269   The Role of Veterinary Research in Human Society KarinCA 04/02/20 09:15:05 PM
#290268   No amount of pumping or actual good news TheDane 04/02/20 09:11:51 PM
#290265   Exactly. Thank You William Cassius Longinus 04/02/20 08:55:30 PM
#290264   Wouldn't you love your doctor POSTING 24-7 on Paddleboarder 04/02/20 08:55:15 PM
#290262   Not sure that’s exactly factual About CytoDyn. Their BioInvestor4 04/02/20 08:46:18 PM
#290261   When this is all said and done, Leo, PJ007 04/02/20 08:40:47 PM
#290260   With three different successful phase 2 trials with steelyeye 04/02/20 08:31:16 PM
#290259   I was wondering about that myself... Minnesinger 04/02/20 08:29:56 PM
#290258   Thanks Pete! Leo is going full steam DaubersUP 04/02/20 08:24:28 PM
#290257   With expected good results ... FDA/CDC is expected Justfactsmam 04/02/20 08:19:12 PM
#290256   It’s exactly as I imagined it. Stuff is TheDane 04/02/20 08:18:23 PM
#290255   Good luck to any who think this company steelyeye 04/02/20 08:15:34 PM
#290254   When IPIX gets funded via JV/partnership it will steelyeye 04/02/20 08:13:55 PM
#290253   Also I don't know if we have considered rrr1 04/02/20 08:08:43 PM
#290252   Interesting you say that since you have been williamssc 04/02/20 08:07:41 PM
#290251   I am relaying a post I saw elsewhere petemantx 04/02/20 08:07:29 PM
#290250   Nobody losing hope or panicking. Au contraire. taas 04/02/20 08:06:04 PM
#290249   #DDAmanda Chart on: $IPIX : Zardiw 04/02/20 08:05:32 PM
#290248   I think good results would put Leo in williamssc 04/02/20 08:01:42 PM
#290247   do you mean 9.5 cents? Gee I hope so. To infinity and beyond! 04/02/20 07:56:27 PM
#290246   Posts like this pick me up a bit livefree_ordie 04/02/20 07:28:50 PM
#290245   I expect news on Tuesday and maybe Monday. Phoenix300 04/02/20 07:23:33 PM
#290244   The last round of news pretty much certifies that. williamssc 04/02/20 07:23:06 PM
#290243   Thank you for the info. I appreciate it BioInvestor4 04/02/20 07:21:38 PM
#290240   Dr Birk is on Portal Facebook on Fox Here Today 04/02/20 07:14:40 PM
#290239   Dr Birkenstock’s is on Portal Facebook on Fox Here Today 04/02/20 07:14:04 PM
#290238   Very well thought out Post Pete. $IPIX eyes rrr1 04/02/20 07:07:57 PM
#290237   Lol! That sticky was taken down fast so Cognition 04/02/20 07:06:00 PM
#290236   Yes it is close but still up a williamssc 04/02/20 07:05:22 PM
#290235   Take a look on the last PR it rrr1 04/02/20 07:05:15 PM
PostSubject